Ergoteles’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Ergoteles’s Portfolio SCPS Stock Details SCPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-23,450	Closed	-$167K	–	1826
2021 Q2	$167K	Buy	+23,450	New	+$167K	﹤0.01%	1331

Other funds holding SCPS

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's SCPS Position: Q3 2021 in Review

Ergoteles sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q3 2021, closing a stake of 23,450 shares — an estimated $167K sold.

Ergoteles first reported a position in SCPS in Q2 2021 and held it in 1 quarter. The position peaked at $167K in Q2 2021. 14 funds tracked by Wall St. Rank hold SCPS as of Q3 2021.

Ergoteles reported no remaining Scopus BioPharma Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 23,450 Scopus BioPharma Inc. Common Stock shares in Q3 2021, an estimated $167K.
Ergoteles first reported a position in Scopus BioPharma Inc. Common Stock in Q2 2021 and held it in 1 quarter.
Ergoteles's Scopus BioPharma Inc. Common Stock position peaked at $167K in Q2 2021.
14 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.